J-T Maul1, A A Navarini1, R Sommer2, F Anzengruber1, C Sorbe2, U Mrowietz3, M Drach1, C Blome2, W-H Boehncke4,5, D Thaci6, K Reich7, R von Kiedrowski8, A Körber9, N Yawalkar10, C Mainetti11, E Laffitte4, M Streit12, S Rustenbach2, C Conrad13, L Borradori10, M Gilliet13, A Cozzio14, P Itin15, P Häusermann15, L E French1, M A Radtke2, M Augustin2. 1. Department of Dermatology, University Hospital Zurich, Zurich, Switzerland. 2. Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany. 3. Department of Dermatology, University Medical Center Schleswig-Holstein, Kiel, Germany. 4. Department of Dermatology and Venereology, Geneva University Hospitals, Geneva, Switzerland. 5. Department of Pathology and Immunology, Geneva University Hospitals, Geneva, Switzerland. 6. Comprehensive Center for Inflammation Medicine, University Hospital Schleswig-Holstein, Lübeck, Germany. 7. Dermatologikum Berlin and SCIderm Research Institute, Hamburg, Germany. 8. Dermatology Practice and CMS3, Selters, Germany. 9. Dermatology Practice Essen, Essen, Germany. 10. Department of Dermatology, Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland. 11. Department of Dermatology, Regional Hospital Bellinzona, Bellinzona, Switzerland. 12. Department of Dermatology, Cantonal Hospital Aarau, Aarau, Switzerland. 13. Department of Dermatology, University Hospital Lausanne, Lausanne, Switzerland. 14. Department of Dermatology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland. 15. Department of Dermatology, University Hospital Basel, Basel, Switzerland.
Abstract
BACKGROUND: Though patient needs are key drivers of treatment decisions, they are rarely systematically investigated in routine care. OBJECTIVE: This study aimed at analysing needs and expectations from the patient perspective in the German and Swiss psoriasis registries PsoBest and Swiss Dermatology Network of Targeted Therapies (SDNTT) with respect to treatment choice, age and gender. METHODS: The German and Swiss psoriasis registries observe patients recruited at first-time use of systemic drugs. Within 10 years, clinical [Psoriasis Area Severity Index (PASI), Body Surface Area (BSA)] and patient-reported outcomes are documented, including the Dermatology Quality of Life Index (DLQI) and the Patient Benefit Index (PBI), characterizing patient needs for treatment. The analysis data set includes n = 4894 patients from PsoBest and n = 449 from SDNTT with mean follow-up time of 7.5 months. RESULTS: A total of 5343 patients registered between 2008 and 2016 were included in the analyses (at baseline: 59.6% male, mean age 47.6 years ± 14.5, PASI 14.2 ± 9.7, BSA 22.7 ± 19.7, DLQI 11.3 ± 7.2). The most important patient needs were to 'get better skin quickly' and to 'be healed of all skin defects'. Subgroup analyses by age revealed significant differences in needs, especially higher needs regarding social impairments in patients younger than 65 years. Patients 65 years or older attributed more importance to sleep quality, less dependency on medical visits, fewer side-effects and confidence in the therapy. Out of 25 items reflecting patient needs, 20 items were rated significantly more important by women than men, with the greatest differences regarding feeling of depression, sleep quality and everyday productivity. Divided by treatment, needs were rated differently, recommending individualized and targeted choice of therapy. CONCLUSION: Age and gender stratify patient needs. Women showed higher expectations and rated specific needs in psoriasis treatment higher than men. Analysing the patient needs on an individual level will facilitate shared decisions by patient and physician in finding the optimal personalized treatment.
BACKGROUND: Though patient needs are key drivers of treatment decisions, they are rarely systematically investigated in routine care. OBJECTIVE: This study aimed at analysing needs and expectations from the patient perspective in the German and Swiss psoriasis registries PsoBest and Swiss Dermatology Network of Targeted Therapies (SDNTT) with respect to treatment choice, age and gender. METHODS: The German and Swiss psoriasis registries observe patients recruited at first-time use of systemic drugs. Within 10 years, clinical [Psoriasis Area Severity Index (PASI), Body Surface Area (BSA)] and patient-reported outcomes are documented, including the Dermatology Quality of Life Index (DLQI) and the Patient Benefit Index (PBI), characterizing patient needs for treatment. The analysis data set includes n = 4894 patients from PsoBest and n = 449 from SDNTT with mean follow-up time of 7.5 months. RESULTS: A total of 5343 patients registered between 2008 and 2016 were included in the analyses (at baseline: 59.6% male, mean age 47.6 years ± 14.5, PASI 14.2 ± 9.7, BSA 22.7 ± 19.7, DLQI 11.3 ± 7.2). The most important patient needs were to 'get better skin quickly' and to 'be healed of all skin defects'. Subgroup analyses by age revealed significant differences in needs, especially higher needs regarding social impairments in patients younger than 65 years. Patients 65 years or older attributed more importance to sleep quality, less dependency on medical visits, fewer side-effects and confidence in the therapy. Out of 25 items reflecting patient needs, 20 items were rated significantly more important by women than men, with the greatest differences regarding feeling of depression, sleep quality and everyday productivity. Divided by treatment, needs were rated differently, recommending individualized and targeted choice of therapy. CONCLUSION: Age and gender stratify patient needs. Women showed higher expectations and rated specific needs in psoriasis treatment higher than men. Analysing the patient needs on an individual level will facilitate shared decisions by patient and physician in finding the optimal personalized treatment.
Authors: Thomas Graier; Wolfgang Weger; Paul-Gunther Sator; Wolfgang Salmhofer; Barbara Gruber; Constanze Jonak; Claudia Kölli; Martina Schütz-Bergmayr; Igor Vujic; Gudrun Ratzinger; Nina Häring; Clemens Painsi; Knut Prillinger; Alexander Mlynek; Hans Skvara; Hannes Trattner; Adrian Tanew; Roland Lichem; Christina Ellersdorfer; Franz Legat; Alexandra Gruber-Wackernagel; Angelika Hofer; Erich Schmiedberger; Wolfram Hoetzenecker; Robert Müllegger; Werner Saxinger; Franz Quehenberger; Peter Wolf Journal: JAAD Int Date: 2020-12-26
Authors: Marloes E van Muijen; S Atalay; L J van Vugt; L M D Vandermaesen; J M P A van den Reek; E M G J de Jong Journal: Drugs Real World Outcomes Date: 2021-03-28
Authors: Carlos Pelayo Hernández-Fernández; Gregorio Carretero; Raquel Rivera; Carlos Ferrándiz; Esteban Daudén; Pablo de Cueva; Isabel Belinchón; Francisco Javier Gómez-García; Enrique Herrera-Acosta; Diana P Ruiz-Genao; Marta Ferrán; Mercé Alsina; Ofelia Baniandrés-Rodríguez; José Luis Sánchez-Carazo; Rafael Botella-Estrada; Antonio Sahuquillo-Torralba; Lourdes Rodríguez; Jaime Vilar-Alejo; Carmen García-Donoso; José M Carrascosa; Mar Llamas-Velasco; Enrique Herrera-Ceballos; Jose Luis López-Estebaranz; Conrad Pujol-Marco; Miguel Angel Descalzo; Ignacio Garcia-Doval Journal: Acta Derm Venereol Date: 2021-01-04 Impact factor: 3.875
Authors: Marieke E C van Winden; Elke L M ter Haar; Hans M M Groenewoud; Peter C M van de Kerkhof; Elke M G J de Jong; Satish F K Lubeek Journal: Acta Derm Venereol Date: 2020-07-28 Impact factor: 3.875
Authors: Neuza da Silva; Matthias Augustin; Anna Langenbruch; Ulrich Mrowietz; Kristian Reich; Diamant Thaçi; Wolf-Henning Boehncke; Natalia Kirsten; Alexandra Danckworth; Rachel Sommer Journal: PLoS One Date: 2020-07-01 Impact factor: 3.240